Correlation of increased serum leucine-rich α2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study.
Aged
Autoantibodies
/ blood
Biomarkers
/ blood
Blood Gas Analysis
C-Reactive Protein
/ analysis
Case-Control Studies
Dermatomyositis
/ complications
Disease Progression
Female
Ferritins
/ blood
Glycoproteins
/ blood
Humans
Interferon-Induced Helicase, IFIH1
/ immunology
Lung Diseases, Interstitial
/ complications
Male
Middle Aged
Prognosis
Retrospective Studies
Survival Rate
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
01
2020
accepted:
18
05
2020
entrez:
2
6
2020
pubmed:
2
6
2020
medline:
26
8
2020
Statut:
epublish
Résumé
To investigate whether leucine-rich α2-glycoprotein (LRG) can be a biomarker for the disease activity, progression, and prognosis of interstitial pneumonia (IP) in patients with dermatomyositis (DM). Correlations between the clinical findings and serum LRG levels were investigated in 46 patients with DM-IP (33 with acute/subacute IP [A/SIP] and 13 patients with chronic IP [CIP], including 10 fatal cases of IP). The median serum LRG level of 18.4 (14.6-25.2) μg/mL in DM-IP patients was higher than that in healthy control subjects. The median levels of serum LRG at baseline and at 2 and 4 weeks after the initiation of treatment in the patients who died were significantly higher than those in the surviving patients (P = 0.026, 0.029, and 0.008, respectively). The median level of serum LRG in the DM-A/SIP patients was significantly higher than that in the DM-CIP patients (P = 0.0004), and that in the anti-MDA5-Ab-positive group was slightly higher than that in the anti-ARS-Ab-positive group. The serum LRG levels correlated significantly with the serum levels of LDH, C-reactive protein, ferritin, AaDO2, %DLco, and total ground-glass opacity score. The survival rate after 24 weeks in patients with an initial LRG level ≥ 17.6 μg/mL (survival rate: 40%) was significantly lower than that in patients with an initial LRG level < 17.6 μg/mL (100%) (P = 0.0009). The serum LRG level may be a promising marker of disease activity, progression, and prognosis in patients with DM-IP.
Identifiants
pubmed: 32479560
doi: 10.1371/journal.pone.0234090
pii: PONE-D-19-34203
pmc: PMC7263588
doi:
Substances chimiques
Autoantibodies
0
Biomarkers
0
Glycoproteins
0
LRG1 protein, human
0
C-Reactive Protein
9007-41-4
Ferritins
9007-73-2
IFIH1 protein, human
EC 3.6.1.-
Interferon-Induced Helicase, IFIH1
EC 3.6.4.13
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0234090Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Rheumatology (Oxford). 2010 Sep;49(9):1713-9
pubmed: 20498012
Nature. 2013 Jul 18;499(7458):306-11
pubmed: 23868260
Rheumatology (Oxford). 2014 Dec;53(12):2196-203
pubmed: 24970922
PLoS One. 2016 Sep 09;11(9):e0162672
pubmed: 27611322
Oncotarget. 2015 May 10;6(13):11009-22
pubmed: 25826092
Dermatol Clin. 2002 Jul;20(3):387-408
pubmed: 12170874
AJR Am J Roentgenol. 1997 Oct;169(4):977-83
pubmed: 9308447
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
Ann Rheum Dis. 2010 Apr;69(4):770-4
pubmed: 19854709
Clin Exp Rheumatol. 1996 May-Jun;14(3):263-74
pubmed: 8809440
N Engl J Med. 1975 Feb 20;292(8):403-7
pubmed: 1089199
Mod Rheumatol. 2018 Jan;28(1):133-140
pubmed: 28490218
Biomed Res Int. 2014;2014:815245
pubmed: 24800252
PLoS One. 2014 Feb 21;9(2):e89610
pubmed: 24586910
Arthritis Rheumatol. 2015 May;67(8):2056-60
pubmed: 25917892
Rheumatology (Oxford). 2018 Jul 1;57(7):1212-1221
pubmed: 29596687
J Am Acad Dermatol. 2006 Apr;54(4):597-613
pubmed: 16546580
PLoS One. 2017 Jan 12;12(1):e0170261
pubmed: 28081565
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64
pubmed: 10673212
Sci Rep. 2017 Mar 06;7:43732
pubmed: 28262744
Arthritis Rheum. 1985 Mar;28(3):249-55
pubmed: 3977973
Inflamm Bowel Dis. 2012 Nov;18(11):2169-79
pubmed: 22374925
Scand J Rheumatol. 2015;44(5):399-403
pubmed: 26079682
Proc Natl Acad Sci U S A. 1985 Apr;82(7):1906-10
pubmed: 3856868
Rheumatology (Oxford). 2012 Sep;51(9):1563-70
pubmed: 22589330
Intern Med. 2010;49(5):361-9
pubmed: 20190466
Rheumatol Int. 2017 Aug;37(8):1335-1340
pubmed: 28451794
Mod Rheumatol. 2015 Jan;25(1):85-9
pubmed: 24716595
Sci Rep. 2017 May 9;7(1):1635
pubmed: 28487565
Biochem Biophys Res Commun. 2009 May 15;382(4):776-9
pubmed: 19324010
Physiol Rep. 2017 Dec;5(24):
pubmed: 29279415
Hoppe Seylers Z Physiol Chem. 1977 Jun;358(6):639-46
pubmed: 69600
J Crohns Colitis. 2017 Jan;11(1):84-91
pubmed: 27466171
J Rheumatol. 2008 Feb;35(2):260-9
pubmed: 18085731